{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:54:36Z","timestamp":1790175276499,"version":"4.1.0"},"reference-count":55,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T00:00:00Z","timestamp":1452470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0146115","type":"journal-article","created":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T19:13:04Z","timestamp":1452539584000},"page":"e0146115","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides\/Sezary Syndrome Alone or with Doxorubicin"],"prefix":"10.1371","volume":"11","author":[{"given":"Lilach","family":"Moyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataly","family":"Feldbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neta","family":"Goldfeiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Rephaeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Nudelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Weitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataly","family":"Tarasenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batia","family":"Gorovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Maron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiran","family":"Yehezkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Amitay-Laish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ido","family":"Lubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmilia","family":"Hodak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,1,11]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.det.2015.06.001","article-title":"Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma","volume":"33","author":"EA Olsen","year":"2015","journal-title":"Dermatol Clin"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2013.07.049","article-title":"Primary cutaneous Tcell lymphoma (mycosis fungoides and S\u00e9zary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers","volume":"70","author":"SI Jawed","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases","volume":"113","author":"PT Bradford","year":"2009","journal-title":"Blood"},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/13543784.2014.876407","article-title":"Novel therapies for cutaneous T-cell lymphoma: what does the future hold?","volume":"23","author":"E Guenova","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/j.seminhematol.2013.11.004","article-title":"Novel therapeutic strategies for cutaneous T-cell lymphoma in advanced stages","volume":"51","author":"L Kun","year":"2014","journal-title":"Semin Hematol"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.5507\/bp.2013.085","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"158","author":"J Hrabeta","year":"2014","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/B978-0-12-394387-3.00005-7","article-title":"Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity","volume":"116","author":"GM Matthews","year":"2012","journal-title":"Adv Cancer Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.biocel.2008.08.027","article-title":"Acetylation of non-histone proteins modulates cellular signaling at multiple levels","volume":"41","author":"S Spange","year":"2009","journal-title":"Int J Biochem Cell Biol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.0022-202X.2005.23925.x","article-title":"Selective induction of apoptosis by histonedeacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action","volume":"125","author":"C Zhang","year":"2005","journal-title":"J Invest Dermatol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1517\/13543784.16.7.1111","article-title":"Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma","volume":"16","author":"M Duvic","year":"2007","journal-title":"Exp Opin Invest Drugs"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e519","DOI":"10.1038\/cddis.2013.9","article-title":"HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses","volume":"4","author":"JE Bolden","year":"2013","journal-title":"Cell Death and Disease"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"RL Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1158\/1078-0432.CCR-08-2785","article-title":"Clinical studies of histone deacetylase inhibitors","volume":"15","author":"HM Prince","year":"2009","journal-title":"J Clin Cancer Res"},{"issue":"1\u20132","key":"ref14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1615\/CritRevOncog.2014012378","article-title":"Drug Combinations with HDAC Inhibitors in Antitumor Therapy","volume":"20","author":"N Arrighetti","year":"2015","journal-title":"Crit Rev Oncog"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/B978-0-12-394387-3.00006-9","article-title":"Histone deacetylase inhibitors and rational combination therapies","volume":"116","author":"S Grant","year":"2012","journal-title":"Adv Cancer Res"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jaad.2008.11.889","article-title":"A novel regimen of vorinostat with interferon gamma for refractory S\u00e9zary syndrome","volume":"61","author":"JM Gardner","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1365-2133.2012.10905.x","article-title":"Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions","volume":"167","year":"2012","journal-title":"Br J Dermatol"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.jaad.2011.06.043","article-title":"Romidepsin and interferon gamma: a novel combination for refractory cutaneous T-cell lymphoma","volume":"68","author":"S Samimi","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.pharmthera.2014.04.004","article-title":"Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights","volume":"143","author":"P Bose","year":"2014","journal-title":"Pharmacol Ther"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/B978-0-12-394387-3.00003-3","article-title":"HDAC inhibitors: roles of DNA damage and repair","volume":"116","author":"C Robert","year":"2012","journal-title":"Adv Cancer Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"4863","DOI":"10.1158\/0008-5472.CAN-05-3410","article-title":"Doxorubicin-DNA Adducts Induce a Non-Topoisomerase II\u2013Mediated Form of Cell Death","volume":"66","author":"P S Lonnie","year":"2006","journal-title":"Cancer Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1158\/1078-0432.CCR-08-2785","article-title":"Clinical studies of histone deacetylase inhibitors","volume":"15","author":"HM Prince","year":"2009","journal-title":"J Clin Cancer Res"},{"issue":"3","key":"ref23","first-page":"5","article-title":"Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents","volume":"4","author":"T Jiahuai","year":"2010","journal-title":"Journal of Hematology & Oncology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/1098-2299(200007\/08)50:3\/4<379::AID-DDR20>3.0.CO;2-8","article-title":"Prodrugs of butyric acid from bench to bedside: synthetic design, mechanisms of action and clinical applications","volume":"50","author":"A Rephaeli","year":"2000","journal-title":"Drug Dev Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ijc.21030","article-title":"In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer","volume":"116","author":"A Rephaeli","year":"2005","journal-title":"Int J Cancer"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00432-006-0116-6","article-title":"Mode of interaction between butyroyloxymethyl-diethyl phosphate (AN-7) and doxorubicin in MCF-7 and resistant MCF-7\/Dx cell lines","volume":"132","author":"D Engel","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10637-006-6213-1","article-title":"The selectivity and anti-metastatic activity of oral bioavailable butyric acid prodrugs","volume":"24","author":"A Rephaeli","year":"2006","journal-title":"Invest New Drugs"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s10585-008-9179-x","article-title":"Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex)","volume":"25","author":"N Tarasenko","year":"2008","journal-title":"Clin Exp Metastasis"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"e31393","DOI":"10.1371\/journal.pone.0031393","article-title":"Disparate impact of butyroyloxymethyl diethylphosphate (AN-7), a histone deacetylase inhibitor, and doxorubicin in mice bearing mammary tumor","volume":"7","author":"N Tarasenko","year":"2012","journal-title":"PLoS One"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s10637-010-9542-z","article-title":"The histone deacetylase inhibitory butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity","volume":"30","author":"N Tarasenko","year":"2012","journal-title":"Invest New Drugs"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2133.1984.tb04727.x","article-title":"Establishment of T and B cell lines from patients with mycosis fungoides","volume":"111","author":"K Kaltoft","year":"1984","journal-title":"Br J Dermatol"},{"issue":"3","key":"ref32","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1089\/aid.1989.5.253","article-title":"Origin of the HIV-susceptible human CD4+ cell line H9","volume":"5","author":"DL Mann","year":"1989","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"E Olsen","year":"2007","journal-title":"Blood"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"TC Chou","year":"2010","journal-title":"Cancer Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2174\/1568009043481560","article-title":"Targeted histone deacetylase inhibition for cancer therapy","volume":"4","author":"DM Vigushin","year":"2004","journal-title":"Curr Cancer Drug Targets"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/cdd.2011.71","article-title":"SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis","volume":"12","author":"D Li","year":"2011","journal-title":"Cell Death Differ"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/bjc.2012.576","article-title":"A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth","volume":"108","author":"M Kaliszczak","year":"2013","journal-title":"Br J Cancer"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1182\/blood-2007-08-109074","article-title":"Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in S\u00e9zary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression","volume":"111","author":"E Contassot","year":"2008","journal-title":"Blood"},{"issue":"6","key":"ref39","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.jaad.2012.05.035","article-title":"The Fas apoptotic pathway in cutaneous T-cell lymphomas: frequent expression of phenotypes associated with resistance to apoptosis","volume":"67","author":"N Stutz","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"ref40","first-page":"75","article-title":"Management of cutaneous T cell lymphoma: new and emerging targets and treatment options","volume":"4","author":"JY Li","year":"2012","journal-title":"Cancer Manag Res"},{"key":"ref41","first-page":"1273","article-title":"Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells","volume":"2","author":"R Rosato","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"161","DOI":"10.5507\/bp.2013.085","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"158","author":"J Hrabeta","year":"2013","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nbt.2284","article-title":"Combinatorial drug therapy for cancer in the post-genomic era","volume":"30","author":"B Al-Lazikani","year":"2012","journal-title":"Nat Biotechnol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2217\/fon.11.2","article-title":"Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer","volume":"7","author":"KT Thurn","year":"2011","journal-title":"Future Oncol"},{"key":"ref45","first-page":"659254","article-title":"Combined treatment with low concentrations of decitabine and SAHA causes cell death in leukemic cell lines but not in normal peripheral blood lymphocytes","author":"B Brodsk\u00e1","year":"2013","journal-title":"Biomed Res Int"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1172\/JCI64503","article-title":"Efficacious proteasome\/HDAC inhibitor combination therapy for primary effusion lymphoma","volume":"123","author":"S Bhatt","year":"2013","journal-title":"J Clin Invest"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/1471-2407-13-286","article-title":"The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells","volume":"13","author":"K Kerl","year":"2013","journal-title":"BMC Cancer"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jphotobiol.2014.01.009","article-title":"Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells","volume":"131","author":"JJ Sung","year":"2014","journal-title":"J Photochem Photobiol B"},{"issue":"3","key":"ref49","first-page":"218","article-title":"Anthracycline-mediated cardiomyopathy: basic molecular knowledge for the cardiologist","volume":"84","author":"J Salazar-Mendiguch\u00eda","year":"2014","journal-title":"Arch Cardiol Mex"},{"issue":"25","key":"ref50","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2174\/092986709788803312","article-title":"Doxorubicin: the good, the bad and the ugly effect","volume":"16","author":"C Carvalho","year":"2009","journal-title":"Curr Med Chem"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1158\/1078-0432.CCR-08-2786","article-title":"Rational combinations using HDAC inhibitors","volume":"15","author":"M Bots","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.canlet.2014.04.021","article-title":"Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA","volume":"351","author":"U Heinicke","year":"2014","journal-title":"Cancer Lett"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/jor.21274","article-title":"The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy","volume":"29","author":"ER Sampson","year":"2011","journal-title":"J Orthop Res"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"19482","DOI":"10.1073\/pnas.0707828104","article-title":"HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination","volume":"104","author":"S Adimoolam","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1667\/RR0811.1","article-title":"Attenuated DNA damage repair by trichostatin A through BRCA1 suppression","volume":"168","author":"Y Zhang","year":"2007","journal-title":"Radiat Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0146115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T06:21:01Z","timestamp":1589005261000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0146115"}},"subtitle":[],"editor":[{"given":"Bridget","family":"Wagner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,1,11]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,1,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0146115","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,11]]}}}